Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non‐small‐cell lung cancer: A multicenter in vitro diagnostic clinical trial
We aimed to verify the expression status and diagnostic significance of isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC), especially during early stages. Serum IDH1 levels were measured by ELISA. A total of 1223 participants (660 patients with NSCLC, 276 healthy controls [HCs]...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2020-05, Vol.111 (5), p.1739-1749 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1749 |
|---|---|
| container_issue | 5 |
| container_start_page | 1739 |
| container_title | Cancer science |
| container_volume | 111 |
| creator | Sun, Nan Sun, Shouguo Gao, Yibo Li, Yuan Lu, Zhiliang Yuan, Zuyang Che, Yun Huang, Jianbing Mao, Shuangshuang Lei, Yuanyuan Zang, Ruochuan Li, Ning Cui, Wei Qi, Jun Chen, Feng Gao, Jia Wang, Jinling Min, Rong Chen, Yan Shi, Guangli Tan, Fengwei He, Jie |
| description | We aimed to verify the expression status and diagnostic significance of isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC), especially during early stages. Serum IDH1 levels were measured by ELISA. A total of 1223 participants (660 patients with NSCLC, 276 healthy controls [HCs], 95 patients with benign pulmonary conditions [BPCs], 135 patients with other cancers [OCs], and 57 samples with interfering factors) were divided into a training cohort and a validation cohort according to 3 testing centers. The IDH1 concentrations in the NSCLC group were obviously higher than those in the control groups (P |
| doi_str_mv | 10.1111/cas.14387 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7226212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2406502054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4957-caaabf959ba2283a1d47c56c611583b714824dbc9ccee08ffac3af8ae0691b273</originalsourceid><addsrcrecordid>eNp9ksuKFDEUhgtRnHF04QtIwI0ueia3qlS5EJrGGwy40FmHU6lT3RlTSZukRnrnI_gkPpRPYnp6HFTQbBI4Xz7OD39VPWb0lJVzZiCdMiladac6ZkJ2C0Vpc_f6rRYdFfyoepDSJaWikZ28Xx0JzhrVsPa4-n6RrbN5R8JIbArG5ggZyYCb3RDDGj0kJIxAIkASxnki2xgyWk96GyaInzCSMUSSN0gQotuVrxlNtsHvlT74H1-_pQmcK7dB54ib_ZoY8AbjC7Ik0-yyNehzERXrVVkgkMHC2odUBsQ4660BR3K04B5W90ZwCR_d3CfVxetXH1dvF-fv37xbLc8XRna1WhgA6Meu7nrgvBXABqlM3ZiGsboVvWKy5XLoTWcMIm3HEYyAsQWkTcd6rsRJ9fLg3c79hMN-vwhOb6MtmXc6gNV_Trzd6HW40orzhjNeBM9uBDF8njFlPdm0zw8ew5w0F0oJyWjLCvr0L_QyzNGXeJrLjkolG9r-n6JNTTmtZaGeHygTQ0oRx9uVGdX7rujSFX3dlcI--T3jLfmrHAU4OwBfrMPdv016tfxwUP4EfTvOYA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2406502054</pqid></control><display><type>article</type><title>Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non‐small‐cell lung cancer: A multicenter in vitro diagnostic clinical trial</title><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><creator>Sun, Nan ; Sun, Shouguo ; Gao, Yibo ; Li, Yuan ; Lu, Zhiliang ; Yuan, Zuyang ; Che, Yun ; Huang, Jianbing ; Mao, Shuangshuang ; Lei, Yuanyuan ; Zang, Ruochuan ; Li, Ning ; Cui, Wei ; Qi, Jun ; Chen, Feng ; Gao, Jia ; Wang, Jinling ; Min, Rong ; Chen, Yan ; Shi, Guangli ; Tan, Fengwei ; He, Jie</creator><creatorcontrib>Sun, Nan ; Sun, Shouguo ; Gao, Yibo ; Li, Yuan ; Lu, Zhiliang ; Yuan, Zuyang ; Che, Yun ; Huang, Jianbing ; Mao, Shuangshuang ; Lei, Yuanyuan ; Zang, Ruochuan ; Li, Ning ; Cui, Wei ; Qi, Jun ; Chen, Feng ; Gao, Jia ; Wang, Jinling ; Min, Rong ; Chen, Yan ; Shi, Guangli ; Tan, Fengwei ; He, Jie</creatorcontrib><description>We aimed to verify the expression status and diagnostic significance of isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC), especially during early stages. Serum IDH1 levels were measured by ELISA. A total of 1223 participants (660 patients with NSCLC, 276 healthy controls [HCs], 95 patients with benign pulmonary conditions [BPCs], 135 patients with other cancers [OCs], and 57 samples with interfering factors) were divided into a training cohort and a validation cohort according to 3 testing centers. The IDH1 concentrations in the NSCLC group were obviously higher than those in the control groups (P < .001). Area under the receiver operating characteristic curves (AUCs) for discriminating NSCLC patients from controls (HC, BPC, and OC) were 0.870 and 0.745 (sensitivity, 63.3% and 55.0%; specificity, 86.8% and 86.3%) in the training cohort and validation cohort, respectively. The AUCs for discriminating stage 0‐IA lung cancer patients from HCs were 0.907 and 0.788 (sensitivity, 58.6% and 59.1%; specificity, 92.9% and 89.3%) in 2 cohorts, respectively. Isocitrate dehydrogenase 1 showed specificity for NSCLC and had no diagnostic value for other common cancers. Furthermore, IDH1 was significantly reduced in postoperative serum. Isocitrate dehydrogenase 1 shows clinical utility as a serum protein biomarker for the early diagnosis of NSCLC.
This is the first large‐scale study aiming to verify the level and diagnostic value of serum isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC) with well‐designed controls in multicenter‐based cohorts. IDH1 showed high diagnostic efficiency in early stage NSCLC and high specificity for NSCLC comparing to other cancers.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.14387</identifier><identifier>PMID: 32167618</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Biomarkers ; blood biomarker ; Cancer therapies ; Clinical trials ; Dehydrogenases ; diagnosis ; Disease ; early detection ; Enzymes ; Hospitals ; IDH1 ; Isocitrate dehydrogenase ; Lung cancer ; Medical prognosis ; Medical screening ; MicroRNAs ; Mortality ; Mutation ; Non-small cell lung carcinoma ; NSCLC ; Original ; Tomography ; Tumors</subject><ispartof>Cancer science, 2020-05, Vol.111 (5), p.1739-1749</ispartof><rights>2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4957-caaabf959ba2283a1d47c56c611583b714824dbc9ccee08ffac3af8ae0691b273</citedby><cites>FETCH-LOGICAL-c4957-caaabf959ba2283a1d47c56c611583b714824dbc9ccee08ffac3af8ae0691b273</cites><orcidid>0000-0002-0285-5403 ; 0000-0001-6799-5813</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226212/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226212/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32167618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Nan</creatorcontrib><creatorcontrib>Sun, Shouguo</creatorcontrib><creatorcontrib>Gao, Yibo</creatorcontrib><creatorcontrib>Li, Yuan</creatorcontrib><creatorcontrib>Lu, Zhiliang</creatorcontrib><creatorcontrib>Yuan, Zuyang</creatorcontrib><creatorcontrib>Che, Yun</creatorcontrib><creatorcontrib>Huang, Jianbing</creatorcontrib><creatorcontrib>Mao, Shuangshuang</creatorcontrib><creatorcontrib>Lei, Yuanyuan</creatorcontrib><creatorcontrib>Zang, Ruochuan</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Cui, Wei</creatorcontrib><creatorcontrib>Qi, Jun</creatorcontrib><creatorcontrib>Chen, Feng</creatorcontrib><creatorcontrib>Gao, Jia</creatorcontrib><creatorcontrib>Wang, Jinling</creatorcontrib><creatorcontrib>Min, Rong</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Shi, Guangli</creatorcontrib><creatorcontrib>Tan, Fengwei</creatorcontrib><creatorcontrib>He, Jie</creatorcontrib><title>Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non‐small‐cell lung cancer: A multicenter in vitro diagnostic clinical trial</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>We aimed to verify the expression status and diagnostic significance of isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC), especially during early stages. Serum IDH1 levels were measured by ELISA. A total of 1223 participants (660 patients with NSCLC, 276 healthy controls [HCs], 95 patients with benign pulmonary conditions [BPCs], 135 patients with other cancers [OCs], and 57 samples with interfering factors) were divided into a training cohort and a validation cohort according to 3 testing centers. The IDH1 concentrations in the NSCLC group were obviously higher than those in the control groups (P < .001). Area under the receiver operating characteristic curves (AUCs) for discriminating NSCLC patients from controls (HC, BPC, and OC) were 0.870 and 0.745 (sensitivity, 63.3% and 55.0%; specificity, 86.8% and 86.3%) in the training cohort and validation cohort, respectively. The AUCs for discriminating stage 0‐IA lung cancer patients from HCs were 0.907 and 0.788 (sensitivity, 58.6% and 59.1%; specificity, 92.9% and 89.3%) in 2 cohorts, respectively. Isocitrate dehydrogenase 1 showed specificity for NSCLC and had no diagnostic value for other common cancers. Furthermore, IDH1 was significantly reduced in postoperative serum. Isocitrate dehydrogenase 1 shows clinical utility as a serum protein biomarker for the early diagnosis of NSCLC.
This is the first large‐scale study aiming to verify the level and diagnostic value of serum isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC) with well‐designed controls in multicenter‐based cohorts. IDH1 showed high diagnostic efficiency in early stage NSCLC and high specificity for NSCLC comparing to other cancers.</description><subject>Biomarkers</subject><subject>blood biomarker</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Dehydrogenases</subject><subject>diagnosis</subject><subject>Disease</subject><subject>early detection</subject><subject>Enzymes</subject><subject>Hospitals</subject><subject>IDH1</subject><subject>Isocitrate dehydrogenase</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Medical screening</subject><subject>MicroRNAs</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>NSCLC</subject><subject>Original</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ksuKFDEUhgtRnHF04QtIwI0ueia3qlS5EJrGGwy40FmHU6lT3RlTSZukRnrnI_gkPpRPYnp6HFTQbBI4Xz7OD39VPWb0lJVzZiCdMiladac6ZkJ2C0Vpc_f6rRYdFfyoepDSJaWikZ28Xx0JzhrVsPa4-n6RrbN5R8JIbArG5ggZyYCb3RDDGj0kJIxAIkASxnki2xgyWk96GyaInzCSMUSSN0gQotuVrxlNtsHvlT74H1-_pQmcK7dB54ib_ZoY8AbjC7Ik0-yyNehzERXrVVkgkMHC2odUBsQ4660BR3K04B5W90ZwCR_d3CfVxetXH1dvF-fv37xbLc8XRna1WhgA6Meu7nrgvBXABqlM3ZiGsboVvWKy5XLoTWcMIm3HEYyAsQWkTcd6rsRJ9fLg3c79hMN-vwhOb6MtmXc6gNV_Trzd6HW40orzhjNeBM9uBDF8njFlPdm0zw8ew5w0F0oJyWjLCvr0L_QyzNGXeJrLjkolG9r-n6JNTTmtZaGeHygTQ0oRx9uVGdX7rujSFX3dlcI--T3jLfmrHAU4OwBfrMPdv016tfxwUP4EfTvOYA</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Sun, Nan</creator><creator>Sun, Shouguo</creator><creator>Gao, Yibo</creator><creator>Li, Yuan</creator><creator>Lu, Zhiliang</creator><creator>Yuan, Zuyang</creator><creator>Che, Yun</creator><creator>Huang, Jianbing</creator><creator>Mao, Shuangshuang</creator><creator>Lei, Yuanyuan</creator><creator>Zang, Ruochuan</creator><creator>Li, Ning</creator><creator>Cui, Wei</creator><creator>Qi, Jun</creator><creator>Chen, Feng</creator><creator>Gao, Jia</creator><creator>Wang, Jinling</creator><creator>Min, Rong</creator><creator>Chen, Yan</creator><creator>Shi, Guangli</creator><creator>Tan, Fengwei</creator><creator>He, Jie</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PQGLB</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0285-5403</orcidid><orcidid>https://orcid.org/0000-0001-6799-5813</orcidid></search><sort><creationdate>202005</creationdate><title>Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non‐small‐cell lung cancer: A multicenter in vitro diagnostic clinical trial</title><author>Sun, Nan ; Sun, Shouguo ; Gao, Yibo ; Li, Yuan ; Lu, Zhiliang ; Yuan, Zuyang ; Che, Yun ; Huang, Jianbing ; Mao, Shuangshuang ; Lei, Yuanyuan ; Zang, Ruochuan ; Li, Ning ; Cui, Wei ; Qi, Jun ; Chen, Feng ; Gao, Jia ; Wang, Jinling ; Min, Rong ; Chen, Yan ; Shi, Guangli ; Tan, Fengwei ; He, Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4957-caaabf959ba2283a1d47c56c611583b714824dbc9ccee08ffac3af8ae0691b273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers</topic><topic>blood biomarker</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Dehydrogenases</topic><topic>diagnosis</topic><topic>Disease</topic><topic>early detection</topic><topic>Enzymes</topic><topic>Hospitals</topic><topic>IDH1</topic><topic>Isocitrate dehydrogenase</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Medical screening</topic><topic>MicroRNAs</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>NSCLC</topic><topic>Original</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Nan</creatorcontrib><creatorcontrib>Sun, Shouguo</creatorcontrib><creatorcontrib>Gao, Yibo</creatorcontrib><creatorcontrib>Li, Yuan</creatorcontrib><creatorcontrib>Lu, Zhiliang</creatorcontrib><creatorcontrib>Yuan, Zuyang</creatorcontrib><creatorcontrib>Che, Yun</creatorcontrib><creatorcontrib>Huang, Jianbing</creatorcontrib><creatorcontrib>Mao, Shuangshuang</creatorcontrib><creatorcontrib>Lei, Yuanyuan</creatorcontrib><creatorcontrib>Zang, Ruochuan</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Cui, Wei</creatorcontrib><creatorcontrib>Qi, Jun</creatorcontrib><creatorcontrib>Chen, Feng</creatorcontrib><creatorcontrib>Gao, Jia</creatorcontrib><creatorcontrib>Wang, Jinling</creatorcontrib><creatorcontrib>Min, Rong</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Shi, Guangli</creatorcontrib><creatorcontrib>Tan, Fengwei</creatorcontrib><creatorcontrib>He, Jie</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Nan</au><au>Sun, Shouguo</au><au>Gao, Yibo</au><au>Li, Yuan</au><au>Lu, Zhiliang</au><au>Yuan, Zuyang</au><au>Che, Yun</au><au>Huang, Jianbing</au><au>Mao, Shuangshuang</au><au>Lei, Yuanyuan</au><au>Zang, Ruochuan</au><au>Li, Ning</au><au>Cui, Wei</au><au>Qi, Jun</au><au>Chen, Feng</au><au>Gao, Jia</au><au>Wang, Jinling</au><au>Min, Rong</au><au>Chen, Yan</au><au>Shi, Guangli</au><au>Tan, Fengwei</au><au>He, Jie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non‐small‐cell lung cancer: A multicenter in vitro diagnostic clinical trial</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2020-05</date><risdate>2020</risdate><volume>111</volume><issue>5</issue><spage>1739</spage><epage>1749</epage><pages>1739-1749</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>We aimed to verify the expression status and diagnostic significance of isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC), especially during early stages. Serum IDH1 levels were measured by ELISA. A total of 1223 participants (660 patients with NSCLC, 276 healthy controls [HCs], 95 patients with benign pulmonary conditions [BPCs], 135 patients with other cancers [OCs], and 57 samples with interfering factors) were divided into a training cohort and a validation cohort according to 3 testing centers. The IDH1 concentrations in the NSCLC group were obviously higher than those in the control groups (P < .001). Area under the receiver operating characteristic curves (AUCs) for discriminating NSCLC patients from controls (HC, BPC, and OC) were 0.870 and 0.745 (sensitivity, 63.3% and 55.0%; specificity, 86.8% and 86.3%) in the training cohort and validation cohort, respectively. The AUCs for discriminating stage 0‐IA lung cancer patients from HCs were 0.907 and 0.788 (sensitivity, 58.6% and 59.1%; specificity, 92.9% and 89.3%) in 2 cohorts, respectively. Isocitrate dehydrogenase 1 showed specificity for NSCLC and had no diagnostic value for other common cancers. Furthermore, IDH1 was significantly reduced in postoperative serum. Isocitrate dehydrogenase 1 shows clinical utility as a serum protein biomarker for the early diagnosis of NSCLC.
This is the first large‐scale study aiming to verify the level and diagnostic value of serum isocitrate dehydrogenase 1 (IDH1) in non‐small‐cell lung cancer (NSCLC) with well‐designed controls in multicenter‐based cohorts. IDH1 showed high diagnostic efficiency in early stage NSCLC and high specificity for NSCLC comparing to other cancers.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>32167618</pmid><doi>10.1111/cas.14387</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0285-5403</orcidid><orcidid>https://orcid.org/0000-0001-6799-5813</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2020-05, Vol.111 (5), p.1739-1749 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7226212 |
| source | Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; PubMed Central |
| subjects | Biomarkers blood biomarker Cancer therapies Clinical trials Dehydrogenases diagnosis Disease early detection Enzymes Hospitals IDH1 Isocitrate dehydrogenase Lung cancer Medical prognosis Medical screening MicroRNAs Mortality Mutation Non-small cell lung carcinoma NSCLC Original Tomography Tumors |
| title | Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non‐small‐cell lung cancer: A multicenter in vitro diagnostic clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A55%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20isocitrate%20dehydrogenase%201%20as%20a%20serum%20protein%20biomarker%20for%20the%20early%20detection%20of%20non%E2%80%90small%E2%80%90cell%20lung%20cancer:%20A%20multicenter%20in%20vitro%20diagnostic%20clinical%20trial&rft.jtitle=Cancer%20science&rft.au=Sun,%20Nan&rft.date=2020-05&rft.volume=111&rft.issue=5&rft.spage=1739&rft.epage=1749&rft.pages=1739-1749&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.14387&rft_dat=%3Cproquest_pubme%3E2406502054%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2406502054&rft_id=info:pmid/32167618&rfr_iscdi=true |